A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne - Trial NCT06336603
Access comprehensive clinical trial information for NCT06336603 through Pure Global AI's free database. This Phase 4 trial is sponsored by Sun Pharmaceutical Industries Limited and is currently Recruitment Completed. The study focuses on Acne Vulgaris. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Pharmaceutical Industries Limited
Timeline & Enrollment
Phase 4
Nov 15, 2023
Sep 01, 2024
Primary Outcome
The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16.
Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris.
 There is no study assessing Winlevi in combination treatment for acne .Therefore this study
 assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336603
Non-Device Trial